FDAorphan designation65% confidence
Medical Products for Rare Diseases and Conditions
Source: FDA
Why This Matters
Why this matters: provides agency context on orphan designation that may shape timing or evidence expectations for Novartis.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Rheumatology · Still's Disease
- Sub-indication
- General
Related signal: Novartis initiates Phase II trial of MAS825 for Still's Disease